Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of YL201 + ivonescimab in advanced solid tumors
CTR20253697Phase 2Active
- Sponsor
- MediLink Therapeutics
- Start
- Oct 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YL201, ivonescimab in Nonhematologic neoplasms, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), sponsored by MediLink Therapeutics. Started Oct 2025; status: active.
02
Drugs
YL201ivonescimab
03
Conditions
Nonhematologic neoplasmssmall cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253697.